The biggest clinical trial news of 2015 so far, arguably, was a report from Biogen Idec (NASDAQ: BIIB) about a drug meant to do something never done before: repair nerve damage in multiple sclerosis patients and possibly reverse the course of the disease.
The news was also quite ambiguous. In a Jan. 8 release, the company deemed the results “positive,” even though the trial, dubbed RENEW, didn’t prove statistically significant for the most important measure and showed no improvement in two other measures. The full data set is to be unveiled at an unspecified future medical conference, Biogen Idec said.
Hey, check out all the research scientist jobs. Post your resume today!
